NCI Waldenstrom Macroglobulinemia Genome-wide Association Study

A discovery GWAS is performed, consisting of genotyping 221 Waldenstrom macroglobulinemia (WM) cases on the Illumina Omni Express 12v1.1 platform and analyzing the genotypes together with those of 3798 previously genotyped controls in a model taking into account gender, age, and principal components of ancestry (i.e., significant eigenvectors). Directly genotyped data are supplemented by imputation using the Haplotype Reference Consortium.]]>
Inclusion criteria, Cases: Individuals with a confirmed diagnosis of Waldenstrom Macroglobulinemia or lymphoplasmacytic lymphoma who provide informed consent for DNA collection, genetic studies and data-sharing. Inclusion criteria, Controls: Adults with no history of Waldenstrom macroglobulinemia, lymphoplasmacytic lymphoma, or other B-cell malignancy at enrollment who provide informed consent for DNA collection and genetic studies. Exclusion criteria: 1) Diagnosis of monoclonal gammopathy of IgM type; 2) diagnosis of primary B-cell disorder other than Waldenstrom macroglobulinemia or lymphoplasmacytic lymphoma; 3) non-European ancestry ]]>
The deposited data represent the original discovery data from 221 cases of Waldenstrom macroglobulinemia.]]>